John Hohneker

John Hohneker is an experienced member of the Board of Directors for several clinical-stage biotechnology companies, including Artios Pharma, ArriVent Biopharma, Carisma Therapeutics, Curis, Sonata Therapeutics, and Trishula Therapeutics, among others. Hohneker's expertise lies in advancing innovative therapeutics for cancer treatment. Hohneker holds an MD in Medicine from Rutgers Robert Wood Johnson Medical School and a BA in Chemistry from Gettysburg College. Educational background includes completing high school at Brick Township High School.